Mark de Boer
Vorstandsvorsitzender bei Fast Forward Pharmaceuticals BV
Aktive Positionen von Mark de Boer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of Utrecht | Corporate Officer/Principal | 05.06.2009 | - |
Fast Forward Pharmaceuticals BV
 Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Vorstandsvorsitzender | - | - |
Crossbeta Biosciences BV
 Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | Direktor/Vorstandsmitglied | - | - |
Aristi Biotech BV
 Aristi Biotech BV BiotechnologyHealth Technology Aristi Biotech BV is a service company dedicated to the preclinical development of monoclonal antibodies. It offers monoclonal antibody generation, cell line development and immunoassay development services. The company is headquartered in Utrecht, the Netherlands. | Vorstandsvorsitzender | - | - |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Direktor/Vorstandsmitglied | 01.02.2021 | - |
Karriereverlauf von Mark de Boer
Ehemalige bekannte Positionen von Mark de Boer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Vorsitzender | 03.06.2009 | 02.05.2012 |
| Gründer | 10.12.2008 | 02.05.2012 | |
Macrozyme BV
 Macrozyme BV Pharmaceuticals: MajorHealth Technology Macrozyme BV develops pharmaceutical compounds and technologies useful for the diagnosis and treatment of inflammatory disorders, lysosomal storage diseases and diabetes. The company was founded by Hans Aerts in 2001 and is headquartered in Amsterdam, The Netherlands. | Vorstandsvorsitzender | - | 01.01.2003 |
| Tanox Pharma BV | Vorstandsvorsitzender | - | - |
| MOLECULAR PARTNERS AG | Corporate Officer/Principal | - | - |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ | - | - | |
| ░░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░ ░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░ ░░ | ░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░ | - | - | |
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Mark de Boer
| University of Amsterdam | Doctorate Degree |
Statistik
International
| Niederlande | 15 |
| Vereinigte Staaten | 4 |
| Schweiz | 2 |
Operativ
| Chief Executive Officer | 6 |
| Director/Board Member | 5 |
| Founder | 4 |
Sektoral
| Health Technology | 13 |
| Commercial Services | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| Private Unternehmen | 16 |
|---|---|
PanGenetics BV
 PanGenetics BV Miscellaneous Commercial ServicesCommercial Services PanGenetics BV researches and develops antibody-based therapeutic products. It specializes in taking antibodies at the late research stage through to clinical proof of concept. The firm’s advanced programs are PG102, a CD40 antagonist, and PG110, an anti-Nerve Growth Factor antibody for use in chronic pain. The company was founded by Mark de Boer and James W. Larrick in 1995 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
| Tanox Pharma BV | |
Polpharma Biologics Utrecht BV
 Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Commercial Services |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
| 4AZA Bioscience NV | Commercial Services |
Macrozyme BV
Macrozyme BV Pharmaceuticals: MajorHealth Technology Macrozyme BV develops pharmaceutical compounds and technologies useful for the diagnosis and treatment of inflammatory disorders, lysosomal storage diseases and diabetes. The company was founded by Hans Aerts in 2001 and is headquartered in Amsterdam, The Netherlands. | Health Technology |
Infection Control BV
 Infection Control BV Medical SpecialtiesHealth Technology Infection Control BV designs, manufactures, markets and sells disinfection systems. It offers products to the clinics and hospitals. The company is headquartered in Eemnes, the Netherlands. | Health Technology |
CoMentis, Inc.
 CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Fast Forward Pharmaceuticals BV
Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Health Technology |
Simibio BV
 Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Health Technology |
EnCare Biotech BV
 EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Health Services |
Crossbeta Biosciences BV
Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | Health Technology |
Aristi Biotech BV
Aristi Biotech BV BiotechnologyHealth Technology Aristi Biotech BV is a service company dedicated to the preclinical development of monoclonal antibodies. It offers monoclonal antibody generation, cell line development and immunoassay development services. The company is headquartered in Utrecht, the Netherlands. | Health Technology |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
- Börse
- Insiders
- Mark de Boer
- Erfahrung
